{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-24-000030","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2024-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.086997+00:00","generated_at":"2026-05-30T14:36:44.926094+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA approves Novocure's Optune Lua for metastatic NSCLC after platinum progression","bullets":["Optune Lua approved for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in patients with mNSCLC who progressed on/after platinum-based therapy.","Phase 3 LUNAR trial: median OS 13.2 months (Optune Lua + therapy) vs 9.9 months (control); 3.3-month gain (P=0.04).","In PD-1/PD-L1 subgroup, median OS 19.0 months vs 10.8 months; 8.2-month gain (P=0.02).","Device-related AEs in 63.1% of patients; mostly low-grade skin toxicity; no Grade 4/5 or deaths.","First substantial OS improvement in >8 years for this patient population; wearable TTFields device."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-24-000030","json":"https://secwatch.observer/filing/0001645113-24-000030.json","markdown":"https://secwatch.observer/filing/0001645113-24-000030.md","text":"https://secwatch.observer/filing/0001645113-24-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000030/0001645113-24-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000030/nvcr-20241015.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T14:36:44.926094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}